SAB Biotherapeutics Announces Departure of Chief Financial Officer

Core Insights - SAB Biotherapeutics announced the departure of CFO Michael King, who will take on a CEO role at a privately-held oncology company, effective June 4, 2024, while remaining an advisor until the end of the year [1][3] - The Board of Directors has initiated a search for a permanent CFO, with Mark Conley serving as Interim CFO during this transition [2] - The company reaffirmed its fiscal year 2024 outlook and upcoming milestones, including a topline data readout from its Phase 1 study of lead candidate SAB-142 [4] Company Overview - SAB Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing human, multi-targeted, high-potency immunoglobulins (IgGs) for treating immune and autoimmune disorders, specifically targeting type 1 diabetes (T1D) with its lead asset SAB-142 [5] - The company utilizes advanced genetic engineering and antibody science to produce a diverse range of specifically targeted, high-potency human IgGs without the need for human donors or convalescent plasma [5]